New Onset Type 1 Diabetes: Role of Exenatide
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.
研究概览
简要总结
There are many recent advances in insulin treatment of type 1 diabetes, however after a meal sugars are always a concern. There is a drug Exenatide (Byetta) which is FDA approved to treat people with type 2 diabetes which helps correct their glucoses (sugars) after meals. This study is going to test whether this drug can improve the after meal sugars in people with new onset type 1 diabetes. To test this you will be given a dose of exenatide (1.25 mcg) and long acting insulin or inulin alone before the boost. There is also a placebo group (healthy subjects) who do not get any medication before the boost. Insulin levels and other hormones that affect blood glucose as well as your sugar will be measured by a series of blood tests. The role exenatide as compared to insulin alone will be examined to prevent low blood sugars which might occur because of food staying longer in the stomach than usual or due to the suppression of a hormone called glucagon which increases blood sugar. If you qualify you will be given exenatide (Byetta 1.25 mcg) along with insulin or insulin alone. You and the researchers will not know which dose you are taking at any single visit. A total of 20 people in which some will be children aged 12- 18 years will participate, being diagnosed within 3 months of having been found to have type 1 diabetes.
详细描述
The specific aims of this study are to determine the following:
- The role of exenatide as compared to insulin monotherapy in reducing postprandial hyperglycemia.
- The role of exenatide on postprandial glucagon and gastric emptying.
- The effect of long acting insulin on postprandial glucose excursions, glucagon concentrations and gastric emptying.
- Postprandial glucose excursions, glucagon concentrations and gastric emptying in normal healthy controls.
Study Design:
A randomized, non-blinded trial with a crossover design will be used. Following informed consent and with appropriate subject assent, all subjects will have a screening visit. Following the screening visit, subjects with T1DM will undergo 3 studies: Part A (exenatide and long acting insulin), Part B (rapid and long acting insulin) and Part C (long acting insulin only). The subjects will be admitted to the CRC on three separate occasions, at least 3-4 weeks apart. The three studies will be performed in a random order and the randomization will be done using a computerized system. The healthy controls will undergo a single study visit. Except for the absence of diabetes, the healthy controls will be identical to the study subjects. Subjects with new onset diabetes will be compared to healthy controls.
During the study, if blood glucose values in a subject are less than 55 mg/dl, IV glucose of 5-15 grams will be administered to achieve euglycemia (90-130 mg/dl). 1-2 doses of IV glucose should correct hypoglycemia. If more than 3 doses are required to achieve euglycemia, the study will be terminated, the subject will be offered a meal tray and blood sugar rechecked to ensure euglycemia. If blood sugar at any time is more than 350 with moderate ketones, the study will be terminated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age between 12-18 years of age at the time of enrollment.
- •Diagnosed with antibody positive T1DM in the past 3 months.
- •Otherwise healthy except for their TIDM and treated hypothyroidism.
- •Females must have a negative pregnancy test.
- •Hemoglobin equal to or greater than 12 g/dl before each study.
- •Weight greater than 44 kg.
排除标准
- •Any chronic disease: leukemia, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis etc, except for diabetes and hypothyroidism.
- •Any medications that may affect glucose metabolism.
- •Abnormal AST, ALT, amylase, lipase, creatinine (more than 3 times normal values).
- •Lack of a supportive family environment as detected by the clinicians and/or social workers.
- •History of substance abuse (evaluated by medical history and CRAFFT questionnaire which will be administered at the screening visit).
- •Positive pregnancy test in females.
- •Lactating and nursing mothers.
研究组 & 干预措施
Part A
Exenatide and long acting insulin before the boost.
干预措施: Exenatide (Drug)
Part B
Rapid and long acting insulin before the boost
干预措施: Rapid and long acting insulin (Drug)
Part C
long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
干预措施: long acting insulin + rapid acting + 1.25 mcg Exenatide (Drug)
结局指标
主要结局
The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.
时间窗: February 2013
Data for this outcome measure are no longer accessible; the PI has left institution and all efforts to locate the data have been exhausted.
次要结局
- The Role of Exenatide on Postprandial Glucagon and Gastric Emptying.(February 2013)
- Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.(February 2013)